期刊文献+

Achieving therapeutic benefits of inhaled corticosteroids/beta2 agonist in chronic obstructive airway disease 被引量:2

Achieving therapeutic benefits of inhaled corticosteroids/beta2 agonist in chronic obstructive airway disease
原文传递
导出
摘要 Asthma and chronic obstructive pulmonary disease t(COPD) are the two commonest causes of adultairflow obstruction. The fundamental dltterences anti similarities between the pathological mechanisms of asthma and COPD are well recognized.^1 Both asthma and COPD involve inflammation of airway, but the pattern and distribution of inflammation markedly differ between typical patients with asthma and COPD. Chronic lung disease is now the most important long-term pulmonary complication in daily practice, and is associated with prolonged hospitalization and long-term pulmonary and clinical problems.^2 Asthma and chronic obstructive pulmonary disease t(COPD) are the two commonest causes of adultairflow obstruction. The fundamental dltterences anti similarities between the pathological mechanisms of asthma and COPD are well recognized.^1 Both asthma and COPD involve inflammation of airway, but the pattern and distribution of inflammation markedly differ between typical patients with asthma and COPD. Chronic lung disease is now the most important long-term pulmonary complication in daily practice, and is associated with prolonged hospitalization and long-term pulmonary and clinical problems.^2
作者 WANG Zeng-li
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2007年第12期1097-1105,共9页 中华医学杂志(英文版)
关键词 ASTHMA chronic obstructive pulmonary disease CORTICOSTEROID beta2 agonist asthma chronic obstructive pulmonary disease corticosteroid beta2 agonist
  • 相关文献

参考文献10

  • 1Szafranski N,,Cukier A,Ramirez A,Menga G,Sansores R,Nahabediam S,et al.Effect and safety of budesonide-formoterol in the management of chronic obstructive pulmonary disease[].European Respiratory Journal.2003
  • 2Reymolds NA,,Perry CM,Keating GM.Budesonid/formoterol:in chronic obstructive pulmonary disease[].Drugs.2004
  • 3Pawwels RA,,Sears MP,Campbell M,ViUasante C,Huang S,Lindh A,et al.Formoterol as relief medication in asthma:a worldwide safety and effectiveness trial[].European Respiratory Journal.2003
  • 4Celli B,Calverley PM,Amderson JA,Ferguson GT,Jenkins G,Jones PW,et al.The towards a revolution in COPD health (TORCH) study:fluticasone proprionate/salmeterol reduces the rate of exacerbations over 3 years[].Chest.2006
  • 5Jones PW,Calverley PM,Celli B,Anderson JA,Ferguson GT,Jenkins C,et al.The towards a revolution in COPD health (TORCH) study:fluticasone propriorate/salmeterol improves and Austains health status in COPD over 3 years[].Chest.2006
  • 6Ferguson GT,Calvezley PM,Andeison ZA,Celli B,Jenkims C,Jones PN,et al.The towards a revolution in COPD health (TORCH) study:fluticasone preprionate/salmeterol in well tolerated in patients with COPD over 3 years[].Chest.2006
  • 7Zheng JP,Zhong NS,Yan L,Wu Y,Chen P,Wen ZG,et al.The efficacy and safety of fluticasone propriorate 500 mg/salmeterol 50 mg combined via discus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD)[].Chest.2006
  • 8Halpin DM.Evaluating the effectiveness of combination therapy to prevent COPD exacerbation:the value of NNT analysis[].International Journal of Clinical Practice.2005
  • 9Humbert M.The right tools at the right time[].Chest.2006
  • 10Parameswaran K.Treatment strategy for asthma:one for all and all for one[].Chest.2006

同被引文献17

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部